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ABSTRACT
Background and objectives Obtaining consistent 
efficacy beyond 12–24 hours with local anesthetics, 
including extended- release formulations, has been 
a challenging goal. Inflammation resulting from 
surgery lowers the pH of affected tissues, reducing 
neuronal penetration of local anesthetics. HTX-011, an 
investigational, nonopioid, extended- release dual- acting 
local anesthetic combining bupivacaine and low- dose 
meloxicam, was developed to reduce postsurgical pain 
through 72 hours using novel extended- release polymer 
technology. Preclinical studies and a phase II clinical trial 
were conducted to confirm the mechanism of action of 
HTX-011.
Methods In a validated postoperative pain pig model 
and a phase II bunionectomy trial, the analgesic effects 
of HTX-011, oral meloxicam (preclinical only), liposomal 
bupivacaine (preclinical only) and saline placebo were 
evaluated. The optimal meloxicam:bupivacaine ratio for 
HTX-011 and the effect of HTX-011 on incisional tissue 
pH were also evaluated preclinically.
Results Preclinical data demonstrate the ability 
of HTX-011 to address local tissue inflammation as 
demonstrated by a less acidic tissue pH, which was 
associated with potentiated and prolonged analgesic 
activity. In the phase II bunionectomy study, HTX-011 
achieved superior and sustained pain relief through 72 
hours after surgery compared with each component in 
the polymer.
Conclusions Preclinical animal and clinical results 
confirm that the low- dose meloxicam in HTX-011 
normalizes the local pH in the incision, resulting in 
superior and synergistic analgesic activity compared 
with extended- release bupivacaine. HTX-011 represents 
an extended- release local anesthetic with a dual- acting 
mechanism of action that may provide an important 
advancement in the treatment of postoperative pain.
Trial registration number NCT02762929.
InTROduCTIOn
The management of acute postoperative pain 
continues to pose a significant challenge to clinicians 
across all surgical specialties, with the most severe 
pain after surgery occurring in the first 72 hours.1 
Despite the administration of opioid and nonopioid 
analgesics during this timeframe, most patients 
still report that their pain is poorly managed.2 The 
use of opioids is associated with an increased risk 
of opioid- related adverse events such as nausea, 
vomiting, respiratory depression and sedation. 
Along with uncontrolled pain, these adverse events 
have been shown to contribute directly to increased 
length of hospital stay and medical costs.3 More 
effective nonopioid analgesics are needed to reduce 
overreliance on opioids when managing postoper-
ative pain and limit risks of abuse, addiction and 
diversion.
Local anesthetics represent an important alter-
native to the use of systemic opioids, with bupiv-
acaine hydrochloride (HCl), an immediate- release 
amide- type anesthetic, as the most widely used for 
addressing postoperative pain.4 However, bupiva-
caine HCl has a limited duration of action (≤12 
hours). Recent attempts to extend the delivery of 
bupivacaine HCl by using extended- release (ER) 
technology have failed to demonstrate consistent 
clinical activity beyond 24 hours despite evidence of 
extended drug release by prolonged plasma concen-
trations.5 The decreased activity of local anesthetics 
in the presence of inflammation is a well- described 
phenomenon.6 Increased tissue acidity caused by 
the normal inflammatory process from injury, infec-
tion or surgical intervention reduces the penetration 
of local anesthetics (both amide and ester classes) 
such as bupivacaine into nerve cells in the affected 
area,6 leading to diminishing analgesia beginning 
in the first few hours and lasting for several days 
(figure 1). In addition, inflammatory mediators can 
also directly act on nociceptors, leading to periph-
eral sensitization that can further contribute to 
reduced local anesthetic activity.7
HTX-011 is an investigational, ER, fixed- dose, 
dual- acting local anesthetic that contains two active 
ingredients, bupivacaine and low- dose meloxicam. 
Meloxicam was included to reduce the local inflam-
matory response to tissue injury from surgery in 
order to maintain physiologic pH in the microen-
vironment at the surgical site and reduce cytokine- 
induced peripheral sensitization. To achieve an 
ER profile for both bupivacaine and meloxicam, 
HTX-011 uses a novel polymer technology,8 which 
provides simultaneous diffusion of the active ingre-
dients in a controlled manner over 72 hours. Since 
the polymer formulation is somewhat viscous 
and hydrophilic, HTX-011 can be applied to the 
affected tissue in the surgical incision without a 
needle and remains where it is placed, releasing 
both drugs simultaneously through 72 hours.
Here, we present results from a preclinical post-
operative pain model in pigs demonstrating that the 
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Figure 1 Mechanism of bupivacaine penetration into the nerve. BPV, 
bupivacaine.
Table 1 Preclinical treatments
Treatment
duration 
of release 
(days)
Bupivacaine 
concentration
(mg/mL)
Meloxicam 
concentration
(mg/mL)
Preclinical
dose
(mL)
ER- B- 6D 6 176 0 1.8
ER- B/M- 6D 6 176 35 1.8
ER- B- 3D 3 29 0 3.4
ER- M- 3D 3 0 1.8 1.8
ER- B/M- 3D 3 29 1.8 3.4
Normal saline N/A N/A N/A 1.8
Liposomal 
bupivacaine
3 13 0 8.0
3D, 3- day formulation; 6D, 6- day formulation; B, bupivacaine; ER, extended release; 
M, meloxicam; N/A, not applicable.
incorporation of meloxicam in combination with bupivacaine in 
an ER formulation synergistically potentiates the activity of bupi-
vacaine for 72 hours. These findings were evaluated in a phase 
II clinical study in bunionectomy that confirmed the synergistic 
mechanism of action of HTX-011.
MeThOdS
extended-release polymer formulations
Initial preclinical studies were conducted using polymer formu-
lations with a 144- hour (6- day) drug release profile (table 1). 
Liposomal bupivacaine (EXPAREL, Pacira Bioscience, Parsip-
pany, New Jersey, USA) and saline placebo were used as positive 
and negative controls. Once the impact of local inflammation 
on the analgesic activity of ER bupivacaine formulations and the 
mitigating effect of meloxicam on the activity of bupivacaine was 
recognized, formulations were optimized to provide a 72- hour 
(3-day) release profile to address the period after surgery known 
to be most painful.1 For the purposes of comparing the combi-
nation to individual active ingredients, comparable ER formu-
lations containing either bupivacaine alone or meloxicam alone 
were also prepared. Finally, multiple formulations of bupiv-
acaine plus meloxicam with varying ratios were prepared and 
evaluated, resulting in the identification of the final composition 
of HTX-011. In the clinical studies, polymer formulations of 
bupivacaine alone (HTX-002) and meloxicam alone (HTX-009) 
were compared with HTX-011.
Preclinical
This study was performed following approval of an application 
form submitted to the Committee for Ethical Conduct in the 
Care and Use of Laboratory Animals.
Postoperative pain model
An established animal model of postoperative pain in pigs was 
used to evaluate the ability of meloxicam to suppress surgery- 
induced local inflammation and normalize tissue pH, in order 
to potentiate the analgesic activity of bupivacaine.9 Pigs are used 
in the model because of their similarities to humans—they have 
similar innervation patterns of their skin and their pain response 
is predictive of pain measures observed in postoperative 
patients. The study drug (1.8–3.4 mL depending on the formu-
lated concentrations of active ingredients) was administered in 
each treatment group (n=4) subcutaneously into the margins of 
a 3- cm incision made into the pig flank to produce incisional 
pain similar to that of a surgical procedure (online supplemen-
tary figure 1). Evaluation of pain was conducted as described 
in Castel.9 Briefly, the intact side (contralateral to the incised 
side) was tested first as a control measure. Von Frey filaments 
(1–60 g) were applied approximately 0.5 cm proximal to the skin 
incision three times with intervals of 5–10 s. If withdrawal by 
the animal from the stimulus did not occur, a thicker filament 
was applied, but if withdrawal occurred, a thinner filament was 
applied. Greater force to elicit a withdrawal response implies 
less nociceptive sensitivity, which was considered to be due to 
greater analgesia from the test formulation. Postoperative pain, 
as assessed by von Frey filament testing, was reported as the 
force required to elicit a withdrawal response. Von Frey filament 
testing was administered at baseline and at 1, 3, 5, 24, 48, and 
72 hours postdose (assessments at 96, 120, and 144 hours post-
dose were included for the evaluations of the early 6- day release 
formulations).
Investigation of meloxicam/bupivacaine ratios
Polymer fixed- combination formulations with ratios of melox-
icam to bupivacaine ranging from 0 to 0.06 were prepared and 
evaluated in pigs to identify the minimum ratio for clinical use. 
The log of the average von Frey withdrawal force over 24–72 
hours values was plotted against the meloxicam/bupivacaine 
ratio and fit to a sigmoidal Emax model. The final, optimized 
formulation of the combination was designated HTX-011.
Evaluation of meloxicam site of action
To investigate if the effect of meloxicam was locally mediated 
or systemically mediated, an additional group of pigs (n=4) was 
administered a 3- day release ER bupivacaine formulation (ER- B- 
3D; table 1) plus a supratherapeutic dose (twice the maximum 
approved human dose) of oral meloxicam (Loxicom Oral 
Suspension, Norbrook, Overland Park, Kansas, USA) 0.5 mg/kg 
once daily on days 1 through 6.
Effect of HTX-011 on local pH
The effect of HTX-011 on the pH of the tissues at the surgical 
incision was also evaluated in the same pig postoperative pain 
model to confirm the underlying mechanism of action. Inci-
sions were made on the left and right flank of each of 4 pigs. 
The left flank was treated with HTX-011 and the right flank 
was left untreated (sham control). Tissue pH at the incision was 
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Figure 2 Analgesic effect of an ER bupivacaine/meloxicam 
combination formulation (ER- B/M- 6D) compared with an ER 
bupivacaine formulation (ER- B- 6D), liposomal bupivacaine, and saline 
placebo in a pig postoperative pain model. ER, extended release.
measured using needle pH electrodes (Microelectrodes, Bedford, 
New Hampshire, USA) embedded into the subcutaneous tissues 
for 48 hours.
Clinical
The safety and efficacy of HTX-011, matching polymer 
formulations containing only bupivacaine (HTX-002) or only 
meloxicam (HTX-009), and saline placebo (negative control) 
were evaluated in a phase II bunionectomy study ( ClinicalTrials. 
gov: NCT02762929, registered May 2016). The study protocol 
and all amendments were approved by a centralized institutional 
review board (Western Institutional Review Board, Puyallup, 
Washington, USA) and the initial protocol was also approved by a 
local institutional review board (CHRISTUS Health IRB, Irving, 
Texas, USA). All subjects provided written informed consent 
prior to participation in any study- specific procedures. Inclu-
sion and exclusion criteria are included in online supplementary 
table 1. Eligible subjects underwent a unilateral simple Austin- 
type bunionectomy under regional anesthesia with no more than 
20 mL of 1% lidocaine without epinephrine administered as a 
Mayo block. For the purposes of comparing HTX-011 to its 
individual components and the controls, subjects were randomly 
assigned to receive a single dose by instillation into the wound 
of one of the following: HTX-011 (120 mg bupivacaine/3.6 mg 
meloxicam), HTX-002 (120 mg bupivacaine), HTX-009 (3.6 mg 
meloxicam), or saline placebo.
All subjects were required to remain in the clinic for assess-
ments for 72 hours postdose and received opioids as rescue medi-
cation for pain control as needed. Pain intensity was assessed 
in each subject using an 11- point Numeric Rating Scale (NRS), 
where 0 equals no pain and 10 equals worst pain imaginable, and 
analyzed using the area under the curve (AUC) of pain intensity 
scores for each interval. The AUC was analyzed using analysis of 
variance. Endpoints for the study included AUC for pain inten-
sity scores through the first 24, 48, and 72 hours postsurgery. 
X- rays to evaluate bone healing were performed.
ReSuLTS
Preclinical studies
A 6- day ER bupivacaine formulation, ER- B- 6D, was first compared 
with a positive control, liposomal bupivacaine, and a negative 
control, saline placebo. Liposomal bupivacaine demonstrated 
analgesic activity on day 1, but von Frey scores were similar to 
those of saline by 48 hours (figure 2), consistent with published 
clinical results.5 Administration of ER- B- 6D resulted in greater 
analgesia, with a similar pattern of diminishing analgesia after 24 
hours, reaching its nadir at 96 hours. There was a return of anal-
gesic activity by 120 hours that further increased at 144 hours. As 
the period of diminished activity of ER- B- 6D coincided with the 
expected time course of inflammation associated with tissue injury, 
combinations of bupivacaine and a nonsteroidal anti- inflammatory 
drug (NSAID) were evaluated with the goal of reducing local 
inflammation at the surgical site in order to maintain analgesic 
activity from 12 to 120 hours. Testing of a 6- day ER combination 
formulation of bupivacaine and meloxicam, ER- B/M- 6D, resulted 
in a sustained analgesic effect that lasted from the time of adminis-
tration through 144 hours (figure 2).
To assess the relative contributions of its components, the anal-
gesic efficacy of a 3- day release formulation of bupivacaine and 
meloxicam, ER- B/M- 3D, was compared with identical formula-
tions of the individual active ingredients, ER- B- 3D and ER- M- 
3D. ER- B/M- 3D produced a substantially greater analgesic effect 
and maintained it over a longer period than either ER- B- 3D or 
ER- M- 3D (figure 3). ER- B- 3D demonstrated moderate analgesia 
during the first few hours after surgery but this decreased and 
remained low from hour 5 through 72 as evidenced by lower 
values in tolerated maximal force in von Frey fiber testing. By 
contrast, from 24 hours and through 72 hours postdose, pigs 
that received the ER- B/M- 3D tolerated a greater maximal force 
(40.3–60.0 g) compared with those that received ER- B- 3D 
(13.8–19.3 g) or saline placebo (1.1–3.4 g). ER- M- 3D provided 
almost no analgesia throughout the entire study period in these 
animals.
The results observed with the ER- B/M- 3D formulation led to 
a follow- up study to determine whether the effect of meloxicam 
on the activity of bupivacaine required local delivery or could 
be achieved with systemic administration. In a group of pigs 
receiving ER- B- 3D and supratherapeutic daily doses of oral 
meloxicam (n=4), von Frey fiber results were similar to those for 
ER- B- 3D alone, demonstrating that meloxicam must be admin-
istered locally in combination with bupivacaine to produce the 
optimal effect (figure 3).
These results led to a full assessment to select the optimal 
ratio of bupivacaine and meloxicam. The relationship between 
the average von Frey withdrawal force and the meloxicam/bupi-
vacaine ratio is presented in figure 4. The half- maximal effect 
was at a meloxicam/bupivacaine ratio of 0.022. Administration 
of formulations with a meloxicam/bupivacaine ratio of <0.030 
generally resulted in a lower analgesic effect compared with 
formulations with ratios of ≥0.030. Thus, the lowest effec-
tive meloxicam/bupivacaine ratio was determined to be 0.030, 
and concentrations of 29 and 0.9 mg/mL of bupivacaine and 
meloxicam, respectively, were selected for further development 
in a formulation designated HTX-011.
To confirm the proposed mechanism of action, tissue pH at 
the surgical incision was measured after administering HTX-011 
into the margins of a surgical incision in pigs. In the pig model, 
tissue pH at the site of incision with HTX-011 treatment was 
consistently higher from 24 hours through 48 hours post- 
incision compared with control (figure 5). The approximately 
1 pH unit difference observed at 48 hours relates to substantially 
more unionized bupivacaine available to enter the nerve with 
HTX-011 treatment compared with control (7.5% unionized vs 
0.6% unionized, respectively).
Clinical evaluation of hTX-011 and its components
In the phase II clinical study, 237 subjects undergoing bunio-
nectomy were included in the assessment of the individual 
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Figure 3 Analgesia from pig model after surgical incision through 72 
hours following administration of ER bupivacaine plus meloxicam, ER 
meloxicam, ER bupivacaine with and without oral meloxicam, or saline 
placebo. ER, extended release.
Figure 4 Relationship between the average von Frey withdrawal force 
and meloxicam:bupivacaine ratio.
Figure 5 pH of untreated or HTX-011- treated incisional tissue in pig 
postoperative pain model. SE, standard error.
components; 74 received HTX-011, 30 received HTX-002, 30 
received HTX-009, and 103 received saline placebo. Subject 
characteristics were similar across the treatment groups; subjects 
were predominately white women with a mean age of 50 years 
(online supplementary table 2).
As shown in figure 6, subjects who received HTX-011 after 
undergoing bunionectomy exhibited significantly lower pain 
scores over the first 24, 48, and 72 hours (AUC0-24, AUC0-48, and 
AUC0-72) than those who received ER formulations of bupiva-
caine alone (HTX-002), meloxicam alone (HTX-009), or saline 
placebo. Pain curves for HTX-011 and HTX-002 separated 
within the first 5 hours. Similar to the preclinical model, the 
initial analgesic activity following administration of HTX-002 
rapidly diminished and was comparable to placebo by 12 hours. 
Clinical results with HTX-009 were also similar to the preclin-
ical model and indistinguishable from saline placebo.
Although the study was not powered to detect a reduction 
in opioid use between groups, HTX-011 significantly increased 
the time to first opioid rescue and decreased opioid consump-
tion compared with the HTX-009, HTX-002, and saline placebo 
groups (table 2). The overall incidence of any adverse event 
and the types of adverse events with HTX-011 were generally 
comparable to or lower than those for HTX-002 and HTX-009. 
Based on the X- ray results, there was no evidence of delays in 
bone healing in any treatment group.
dISCuSSIOn
Local anesthetics are used in most surgical procedures in the USA 
for postoperative pain management; however, consistent activity 
through the critical first 72 hours after surgery has been chal-
lenging. One barrier to developing a long- acting local anesthetic 
for treating postoperative pain is the ability of the local anes-
thetic to remain active in the local inflammatory, acidified envi-
ronment that occurs as a result of surgery.10 The hypothesis that 
diminished local anesthetic response can be prevented by local 
delivery of meloxicam to control inflammation is supported by 
the results presented here. HTX-011 normalized tissue pH and 
significantly improved analgesic activity and duration of anal-
gesia compared with its individual components.
Causes for diminished local anesthetic activity
The inflammatory process following surgery- associated tissue 
injury initiates several changes in the local tissue environment. 
The first action taken by the body immediately after tissue injury 
is to control bleeding.11 Platelets activate as part of the coagu-
lation cascade and as the clot forms, they release cytokines that 
initiate the inflammatory response.12 Shortly after tissue injury, 
inducible cyclo- oxygenase (COX)-2 is upregulated13 and initi-
ates a cascade of events that results in synthesis of proinflamma-
tory prostaglandins such as prostaglandin E2 (PGE2). Serotonin 
released by platelets as well as the increasing concentrations of 
PGE2 in the presence of bradykinin results in an increase in 
local vascular permeability.14 This, coupled with the concentra-
tion gradient of chemotactic agents such as complement factors, 
interleukin-1, tumor necrosis factor-α, transforming growth 
factor p, and platelet factor 4, stimulates neutrophils to migrate 
into the wound.15 In addition, inflammation leads initially to 
a drop in pH due to local vasoconstriction and resulting isch-
emic conditions; later as a result of infiltration and activation of 
neutrophils in the tissue,11 there is increased energy and oxygen 
demand and accelerated glucose consumption via glycolysis. 
These conditions result in increased lactic acid secretion,16 17 
causing acidification.18 Therefore, the low tissue pH observed is 
likely due to a combination of ischemia and activated leucocytes 
consuming oxygen and releasing acid.
Local anesthetics bind to the sodium voltage- gated ion chan-
nels from the interior of the neuron via the ionized (protonated) 
form. The pKa (pH where 50% of the molecules are union-
ized and 50% are ionized) of all local anesthetics is above the 
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Table 2 Opioid consumption by treatment group
hTX-011
120 mg/3.6 mg
(n=74)
hTX-002
120 mg
(n=30)
hTX-009
3.6 mg
(n=30)
Saline placebo
(n=103)
Median time to first opioid rescue medication (hours) 10.63 6.31 3.83 3.62
  P value versus HTX-011 0.0025 <0.0001 <0.0001
Total opioid use (mg)
0–24 hours
  Mean (SD) 8.55 (8.089) 15.07 (7.987) 16.07 (9.766) 16.75 (8.820)
  P value versus HTX-011 0.0003 0.0001 <0.0001
0–72 hours
  Mean (SD) 23.70 (19.145) 29.40 (18.788) 32.70 (20.742) 32.65 (23.505)
  P value versus HTX-011 0.1699 0.0365 0.0077
Total opioid use is expressed as intravenous milligram morphine equivalents (ie, morphine equivalents). P values from Wilcoxon test (time to first opioid use) and analysis of 
variance (total opioid use).
Figure 6 Mean pain intensity scores through 72 hours following administration of HTX-011, HTX-002, HTX-009, or saline placebo in phase II 
bunionectomy study. AUC0- XX, area under the curve from 0 to XX number of hours. NRS, numeric rating scale; PBO, placebo; SE, standard error.
physiologic pH of 7.4. Therefore, when infiltrated into normal 
tissue, the majority of local anesthetic molecules are in the 
ionized state. However, in order to pass through the neuronal 
membrane, local anesthetics must be unionized19; thus, only 
a fraction of the local anesthetic molecules are able to pass 
through the neuronal membrane (figure 1). Once the unionized 
form enters the nerve, the equilibrium between unionized and 
ionized is reestablished and ionized molecules are available to 
bind to the voltage- gated ion channels.
Inflammation resulting from injury produces an acidic tissue 
environment outside the nerve favoring the ionized form, 
reducing the concentration of molecules available to penetrate 
into the nerve. This effect may explain why even as recent 
attempts to extend the delivery of local anesthetics have resulted 
in prolonging exposure, they have not demonstrated consistent 
pharmacodynamic activity beyond 24 hours.
An emerging line of evidence suggests that peripheral sensi-
tization may also play a role in reducing the activity of local 
anesthetics in the presence of inflammation. PGE2 is known to 
act directly on C- fibers, resulting in a reduced action potential 
threshold leading to peripheral sensitization.20 One pathway by 
which this occurs is PGE2 binding to the EP class of receptors 
on the surface of the nerve, ultimately resulting in upregulation 
and increased excitability of tetrodotoxin- resistant ion channels, 
some of which appear to have low sensitivity to inhibition by 
local anesthetics.21 22
development of hTX-011
HTX-011 utilizes a novel fourth- generation tri(ethylene glycol) 
poly(orthoester) (TEG- POE)- based formulation that is designed 
for parenteral, sustained- release drug delivery applications.8
TEG- POE polymer formulations are semiviscous liquids that 
control drug release via diffusion. The drug release rate from 
these formulations can be adjusted to provide delivery over a 
period of days to weeks by controlling the composition and 
molecular weight of the TEG- POE as well as the selection of 
biocompatible solvent excipients, such as the dimethyl sulfoxide 
and glycerol triacetate used in HTX-011.23 Because drug release 
is controlled by diffusion as opposed to polymer erosion used 
in other ER systems, there is no delayed early phase release, 
preventing the initial delivery of the active ingredient.23 Addi-
tionally, TEG- POE hydrolysis is slow during the delivery phase, 
ensuring that the active ingredients diffuse at a consistent rate. 
TEG- POE polymer is composed of repeating units containing 
a diol connected to an orthoester. Once the active components 
have been released from the formulation, the rate of polymer 
hydrolysis rapidly increases via the cleavage of the orthoester 
bonds, liberating small, water- soluble monomeric compounds 
that are rapidly cleared from the body by the kidneys. These 
compounds do not alter the pH of the local tissue environment.
The novel ER polymer is a component of the FDA- approved 
SUSTOL (granisetron) ER injection for subcutaneous use and has 
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been extensively evaluated in nonclinical safety studies including 
repeated- dose toxicity with daily dosing for 90 days, for in vitro 
and in vivo genotoxicity, and for reproductive and developmental 
toxicity studies in two species. Additional nonclinical toxicology 
studies conducted during the development of HTX-011 revealed 
no findings suggestive of systemic toxicity and no sustained local 
effects. HTX-011 was also extensively evaluated in local toler-
ance studies; briefly, HTX-011 did not demonstrate an effect 
that was meaningfully different compared with bupivacaine HCl 
on bone healing, skin wound healing, wound healing in the pres-
ence of an implant (eg, mesh), or neurotoxicity (data on file).
Initial studies focused on the development of an ER bupivacaine 
formulation. It is known that the analgesic activity of liposomal 
bupivacaine diminishes after 24 hours,5 and it was hypothesized 
that this could be due, in part, to the migration of the liposomes 
away from the pain- generating area. If that is the case, a poly-
meric ER bupivacaine formulation administered directly to the 
wound should remain in contact with pain- generating tissue 
and provide prolonged analgesia. A polymer- based, 6- day ER 
formulation, ER- B- 6D, produced superior activity but dimin-
ishing analgesia after 24 hours; however, an unexpected return 
of analgesic activity was observed after 96 hours. This return of 
activity after 96 hours negated the migration hypothesis but was 
consistent with the expected time course of local inflammation 
produced by surgical insult. The initial inflammatory response 
with resulting drop in tissue pH6 and peripheral sensitization 
subsides with time, with an increasing fraction of bupivacaine in 
the unionized form available to penetrate the nerve membrane 
producing a greater analgesic effect.
In theory, local administration of NSAIDs would be expected 
to limit the local inflammatory response and inhibit the 
production of tissue prostaglandins, thereby reducing the local 
inflammatory- mediated tissue pH drop and peripheral sensiti-
zation. This could prevent the normal loss of clinical efficacy 
beyond the 12- to 24- hour window seen with other ER local 
anesthetics. Screening of various NSAIDs to be coformulated 
with bupivacaine that may alter local inflammation led to the 
selection of meloxicam. The combined formulation demon-
strated sustained analgesic activity over 144 hours in the pig 
postoperative pain model, which was not observed with ER 
bupivacaine alone. In addition, the properties of meloxicam 
made it ideally suited for inclusion into the formulation: high 
potency (allowing for low concentrations and better control of 
drug release), low COX-1 activity with a demonstrated minimal 
impact on clotting, and low cardiovascular risk, especially given 
the short duration and low systemic exposure associated with 
local delivery.24–26 Notably, in the HTX-011 phase III studies 
in bunionectomy and herniorrhaphy, mean maximum concen-
trations of meloxicam (Cmax) were much lower compared with 
the mean maximum concentration of oral meloxicam using the 
lowest recommended dose in a healthy male population (mean 
meloxicam Cmax in phase III studies, 31.6 ng/mL and 181 ng/mL 
[data on file]; Cmax in meloxicam package insert, 1050 ng/mL).
27 
The results of the assessment of bone healing conducted in the 
phase II bunionectomy study (data on file) are consistent with 
studies showing that short- term use of low- dose NSAIDs does 
not interfere with bone healing.28 29
demonstration of synergistic activity of bupivacaine  
and meloxicam
The usual isobologram analysis used to demonstrate synergy 
requires both ingredients of the combination to have activity on 
the measured response in order to generate dose- response curves 
for each individual active ingredient.30 As demonstrated in both 
the pig postoperative pain model and in the phase II bunionec-
tomy study, the meloxicam component of HTX-011 produced 
no appreciable analgesic activity, whereas HTX-011 produced 
significantly greater and prolonged analgesia than either bupi-
vacaine or meloxicam separately. Therefore, the supra- additive 
analgesic activity of HTX-011 over the ER bupivacaine formu-
lation in the bunionectomy phase II study confirms a synergistic 
interaction, with meloxicam potentiating the analgesic activity 
of bupivacaine.
In both preclinical and clinical models, the enhanced analgesic 
activity of formulations of bupivacaine plus meloxicam over 
formulations of bupivacaine alone became apparent within the 
first 5 hours; this was maintained over 72 hours, consistent with 
the period where inflammation would be impacting the activity 
of bupivacaine. This is also consistent with the meloxicam 
component producing a direct effect on the microenvironment 
of the surgical site, as high systemic concentrations of meloxicam 
had no impact on the analgesic activity of bupivacaine. This may 
be due to several factors, such as the need for high local concen-
trations to reduce inflammation in order to normalize the pH 
and to limit peripheral sensitization, as well as local ischemia 
resulting from surgery preventing systemic meloxicam from 
achieving pharmacologically active concentrations in the tissue. 
Further studies will be needed to establish the individual contri-
butions of these effects, but the dramatic synergy resulting in 
significantly increased analgesia is evident in both preclinical and 
clinical studies.
In summary, HTX-011 is a nonopioid, ER, dual- acting local 
anesthetic formulation comprising bupivacaine and low- dose 
meloxicam that uses novel, extended- release polymer tech-
nology. Preclinical data demonstrate the ability of HTX-011 to 
address local tissue inflammation by reducing the drop in tissue 
pH in the incision after surgery compared with control, which 
was associated with potentiated and prolonged analgesic activity. 
The approximately 1 pH unit difference observed at 48 hours 
results in >10- fold more unionized bupivacaine available to enter 
the nerve with HTX-011 treatment compared with control. The 
ability to provide consistent analgesia throughout the critical 72 
hours postoperative period may provide an important option for 
clinicians to manage pain without overreliance on opioids.
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